Literature DB >> 10399955

Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma.

G R Thomas1, Z Chen, M N Oechsli, F J Hendler, C Van Waes.   

Abstract

We established a new syngeneic murine model of oral squamous-cell carcinoma (SCC) to analyze the potential role of immune recognition determinants in the early development of oral cancer. In this study, we examined whether SCC that undergo transformation and development in the absence of specific immunity exhibit differences in tumorigenicity that relate to differences in expression of CD80, CD86 or MHC class I. Mucosal keratinocytes from BALB/c mice were transformed in vitro with 4-nitroquinolone-1-oxide (4-NQO) and inoculated into SCID mice to obtain tumorigenic cell lines. Five SCC cell lines were re-isolated from tumors, and 4 retained cytokeratin and beta4-integrin markers of epithelial origin. Their growth was compared in BALB/c and in congenic SCID mice to establish whether the cell lines exhibit differences in immunogenicity. Three lines that showed slower growth or completely regressed when implanted in immune competent hosts retained or developed increased expression of CD80 during development in SCID mice. Conversely, 2 SCC lines that lost expression of CD80 after passage in vivo grew progressively in immune-competent hosts. MHC-class-I and CD86 expression did not correlate with tumorigenicity. These observations provide evidence that decreased expression of CD80 may serve as a marker for increased tumorigenicity during early development of oral SCC. The development of this new murine oral SCC model should prove useful in determining the potential effects of CD80 expression on the immune pathogenesis and therapy of SCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399955     DOI: 10.1002/(sici)1097-0215(19990730)82:3<377::aid-ijc11>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.

Authors:  Ayman Oweida; Shelby Lennon; Dylan Calame; Sean Korpela; Shilpa Bhatia; Jaspreet Sharma; Caleb Graham; David Binder; Natalie Serkova; David Raben; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Oncoimmunology       Date:  2017-08-03       Impact factor: 8.110

2.  Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC).

Authors:  Nadarajah Vigneswaran; Jean Wu; Anren Song; Ananth Annapragada; Wolfgang Zacharias
Journal:  Exp Mol Pathol       Date:  2011-01-12       Impact factor: 3.362

3.  ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Authors:  Nancy P Judd; Ashley E Winkler; Oihana Murillo-Sauca; Joshua J Brotman; Jonathan H Law; James S Lewis; Gavin P Dunn; Jack D Bui; John B Sunwoo; Ravindra Uppaluri
Journal:  Cancer Res       Date:  2011-11-15       Impact factor: 12.701

Review 4.  Trends in Surgical Research in Head and Neck Cancer.

Authors:  Genrich Tolstonog; Christian Simon
Journal:  Curr Treat Options Oncol       Date:  2017-06

5.  Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.

Authors:  Ayman J Oweida; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Natalie Serkova; Sana D Karam
Journal:  J Vis Exp       Date:  2019-04-22       Impact factor: 1.355

6.  ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.

Authors:  Rifat Hasina; Leslie E Martin; Kristen Kasza; Colleen L Jones; Asif Jalil; Mark W Lingen
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

7.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

Review 8.  Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.

Authors:  Clint T Allen; Paul E Clavijo; Carter Van Waes; Zhong Chen
Journal:  Cancers (Basel)       Date:  2015-12-09       Impact factor: 6.639

Review 9.  Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma.

Authors:  Zhen-Ge Lei; Xiao-Hua Ren; Sha-Sha Wang; Xin-Hua Liang; Ya-Ling Tang
Journal:  Onco Targets Ther       Date:  2016-01-27       Impact factor: 4.147

10.  Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.

Authors:  Ameet K Mishra; Tanya Kadoishi; Xiaoguang Wang; Emily Driver; Zhangguo Chen; Xiao-Jing Wang; Jing H Wang
Journal:  Oncotarget       Date:  2016-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.